These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 29135889)

  • 1. COMPARISON OF RESOLUTION OF VITREOMACULAR TRACTION AFTER OCRIPLASMIN TREATMENT OR VITRECTOMY.
    Scholz P; Sitnilska V; Hess J; Becker M; Michels S; Fauser S
    Retina; 2019 Jan; 39(1):180-185. PubMed ID: 29135889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmaological vitreolysis with ocriplasmin as a treatment option for symptomatic focal vitreomacular traction with or without macular holes (≤400 μm) compared to tranconjunctival vitrectomy].
    Maier M; Abraham S; Frank C; Lohmann CP; Feucht N
    Ophthalmologe; 2017 Feb; 114(2):148-154. PubMed ID: 27444007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surgical Results in Ocriplasmin Candidates With Symptomatic Vitreomacular Traction Syndrome.
    Vasquez DH; Altamirano JC; Casaus A; Del Valle RA; Gonzalez R; Gonzalez-De La Rosa A; Navarro-Partida J; Vasquez MA; Santos A
    Curr Eye Res; 2018 Feb; 43(2):208-212. PubMed ID: 29111823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ocriplasmin versus vitrectomy for the treatment of macular holes.
    Juncal VR; Chow DR; Vilà N; Kapusta MA; Williams RG; Kherani A; Berger AR
    Can J Ophthalmol; 2018 Oct; 53(5):441-446. PubMed ID: 30340707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of intravitreal ocriplasmin treatment for vitreomacular traction in clinical practice.
    Schumann RG; Langer J; Compera D; Luedtke K; Schaumberger MM; Kreutzer T; Mayer WJ; Wolf A; Priglinger SG
    Graefes Arch Clin Exp Ophthalmol; 2017 Nov; 255(11):2081-2089. PubMed ID: 28755165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ocriplasmin Treatment Leads to Symptomatic Vitreomacular Adhesion/Vitreomacular Traction Resolution in the Real-World Setting: The Phase IV ORBIT Study.
    Khanani AM; Duker JS; Heier JS; Kaiser PK; Joondeph BC; Kozma P; Rosberger DF; MacCumber M; Boyer DS; Pieramici DJ
    Ophthalmol Retina; 2019 Jan; 3(1):32-41. PubMed ID: 30935657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subfoveal Lucency after Treatment of Vitreomacular Traction without Macular Hole in the Phase 3 Trials of Ocriplasmin Vitreolysis.
    Thomas AS; Folgar FA; Jaffe GJ; Toth CA; Mahmoud TH
    Ophthalmol Retina; 2019 Jan; 3(1):42-52. PubMed ID: 30929816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short-term changes in posterior vitreous cortex following intravitreal ocriplasmin for symptomatic vitreomacular traction syndrome: a prospective study.
    Cacciamani A; Gattegna R; Pileri M; Di Nicola M; Bardanzellu S; Facciolo G; Cosimi P; Govetto A; Scarinci F
    Int Ophthalmol; 2020 Jan; 40(1):185-193. PubMed ID: 31565760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. OCRIPLASMIN FOR VITREOMACULAR TRACTION IN CLINICAL PRACTICE: The INJECT Study.
    Steel DHW; Patton N; Stappler T; Karia N; Hoerauf H; Patel N; Wachtlin J; Raber T; Kozma-Wiebe P;
    Retina; 2021 Feb; 41(2):266-276. PubMed ID: 32496343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vitrectomy After ocriplasmin for VitreOmacular adhesion Or Macular hole (VAVOOM) study.
    Greven MA; Garg S; Chiu B; Shah SP; Wolfe J; Fine HF; Roth DB; Robinson J; Mong J; Hsu J; Regillo C; Ho A; Haller JA
    Br J Ophthalmol; 2016 Sep; 100(9):1211-5. PubMed ID: 26659344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal ellipsoid zone and subretinal fluid mapping following ocriplasmin injection in the prospective observational ORBIT trial.
    Lavine JA; Srivastava SK; Dukles N; Reese JL; Ehlers JP
    Br J Ophthalmol; 2020 Mar; 104(3):410-415. PubMed ID: 31248879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ocriplasmin treatment for vitreomacular traction in real life: can the indication spectrum be expanded?
    Manousaridis K; Peter-Reichart S; Mennel S
    Graefes Arch Clin Exp Ophthalmol; 2017 Oct; 255(10):1907-1916. PubMed ID: 28681138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of intravitreal ocriplasmin on vitreomacular traction and full-thickness macular holes.
    Sharma P; Juhn A; Houston SK; Fineman M; Chiang A; Ho A; Regillo C
    Am J Ophthalmol; 2015 May; 159(5):861-7.e2. PubMed ID: 25660387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outer retina reflectivity changes on sd-oct after intravitreal ocriplasmin for vitreomacular traction and macular hole.
    Quezada-Ruiz C; Pieramici DJ; Nasir M; Rabena M; Steinle N; Castellarin AA; Dhoot D; Couvillion S; See RF; Avery RL
    Retina; 2015 Jun; 35(6):1144-50. PubMed ID: 25961122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IMPACT OF VITREORETINAL INTERFACE ARCHITECTURE ON SUCCESSFUL VITREOMACULAR TRACTION RESOLUTION IN EYES SCHEDULED FOR INTRAVITREAL OCRIPLASMIN THERAPY.
    Paul C; Heun C; Müller HH; Fauser S; Kaymak H; Kazerounian S; Sekundo W; Mennel S; Meyer CH; Schmitz-Valckenberg S; Koss MJ; Feltgen N; Bertelmann T
    Retina; 2017 Jul; 37(7):1252-1260. PubMed ID: 27787446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does ocriplasmin affect the RPE-photoreceptor adhesion in macular holes?
    Hager A; Seibel I; Riechardt A; Rehak M; Joussen AM
    Br J Ophthalmol; 2015 May; 99(5):635-8. PubMed ID: 25403647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vitreomacular traction quantitative cutoffs for the assessment of resolution after ocriplasmin intravitreal treatment.
    Arrigo A; Calamuneri A; Bordato A; Aragona E; Pierro L; Bandello F; Battaglia Parodi M
    Sci Rep; 2020 Oct; 10(1):17583. PubMed ID: 33067537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Morphological Reconstitution and Persistent Changes After Intravitreal Ocriplasmin for Vitreomacular Traction and Macular Hole.
    Zandi S; Freiberg F; Vaclavik V; Pfister IB; Traine PG; Kaya C; Michels S; Garweg JG
    J Ocul Pharmacol Ther; 2020 Mar; 36(2):126-132. PubMed ID: 31934816
    [No Abstract]   [Full Text] [Related]  

  • 19. Results of the 2-Year Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (OASIS) Randomized Trial.
    Dugel PU; Tolentino M; Feiner L; Kozma P; Leroy A
    Ophthalmology; 2016 Oct; 123(10):2232-47. PubMed ID: 27499517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flare changes after intravitreal injection of ocriplasmin in symptomatic vitreomacular traction syndrome.
    Pirani V; Pelliccioni P; Cesari C; Carrozzi G; Cavallero E; Mariotti C
    Jpn J Ophthalmol; 2019 May; 63(3):255-261. PubMed ID: 30805734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.